Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma

BACKGROUND: Antiangiogenic therapies for malignant gliomas often result in transient response, and recurrent disease is characterized by adoption of invasive and hypoxic phenotype. The notch signaling pathway is activated in gliomas, and augments cell migration and hypoxic response. Here we report a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurooncol
Autors principals: Pan, Edward, Supko, Jeffrey G., Kaley, Thomas J., Butowski, Nicholas A., Cloughesy, Timothy, Jung, Jinkyu, Desideri, Serena, Grossman, Stuart, Ye, Xiaobu, Park, Deric M.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571739/
https://ncbi.nlm.nih.gov/pubmed/27826680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2263-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars